en · de · es · pt
liraglutide-notes.peptides7250.com › Data › Tirzepatide �ˆ†子背景与靶点 — What the Evidence Shows

Tirzepatide �ˆ†子背景与靶点 — What the Evidence Shows

By Editorial Desk · published 2025-08-17 · last reviewed 2025-09-27 · Data

Synthetic peptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2025-09-27. Numbers and descriptions here follow the published literature rather than marketing material.

Tirzepatide 分子背景与靶点

在生理层面,GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素,进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路,使胰岛素分泌的葡萄糖依赖性增强,并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比,双靶点作用在血糖控制和体重变化上的效应幅度更大,但具体贡献比例仍在研究之中。

脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强,从而延长循环半衰期,支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征,减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用,属于既定的药代动力学策略。

该化合物的名称与结构由国际非专利名称体系统一维持,不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。

Background and Molecular Development

Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.

The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.

Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.

Tirzepatide at a glance

PropertyValueNotes
分子类型合成修饰肽39 个氨基酸,含脂肪酸侧链
受体靶点GIP 与 GLP-1 受体双重激动剂
分子量约 4.8 kDa以游离肽计
外观白色至类白色粉末冻干形态常见
溶解性可溶于水及水性缓冲液溶解后宜低温保存

Background and Dual Receptor Pharmacology

Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.

Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.

Related pages on this site

Molecular Basis and Receptor Pharmacology

Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.

At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.

An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.

Supporting material

=== Pests === Common tomato pests include the tomato bug, stink bugs, cutworms, tomato hornworms and tobacco hornworms, aphids, cabbage loopers, whiteflies, tomato fruitworms, flea beetles, red spider mite, Tuta absoluta (tomato leafminer), slugs, and Colorado potato beetles. The tomato russet mite, Aculops lycopersici, feeds on foliage and young fruit of tomato plants, causing shrivelling and necrosis of leaves, flowers, and fruit, possibly killing the plant. After an insect attack tomato plants produce systemin, a plant peptide hormone. This activates defensive mechanisms, such as the production of protease inhibitors to slow the growth of insects. The hormone was first identified in tomatoes.

== Cast == Aaron Kwok as Sean Lau (劉傑輝), Commissioner of Police Tony Leung Ka-fai as M.B. Lee (李文彬), retired Deputy Commissioner of Police (Operations) Chow Yun-fat as Oswald Kan (簡奧偉), Ex-judge, Court of First Instance of High Court / Senior Counsel / Current Legislator Charlie Young as Phoenix Leung (梁紫薇), Senior Assistant Commissioner of Police, Director of Management Services Janice Man as Isabel Au (歐詠恩), Barrister & mentee of Oswald Kan Eddie Peng as Joe Lee (李家俊), Ex-police constable / criminal & son of M.B. Lee Aarif Rahman as Billy Cheung (張國標), ICAC Principal Investigator Tony Yang as Roy Ho, Ex-Senior Police Constable Chang Kuo-chu as Peter Choi (蔡元祺), former Commissioner of Police (Cantonese dub: Kwok Fung) Wu Yue as Wu Tin-man, Ex-Senior Inspector of Police Ma Yili as Michelle Lau (陳雪兒), wife of Sean Lau Bibi Zhou as Alice Poon, Barrister Alex Tsui as Matthew Mak (麥啟文), ICAC Head of Operations Fan Zhibo as Rachel Ma, S.I.P. (VIP Protection Unit) Frankie Lam as Alan Au, current Deputy Commissioner of Police (Management) Kenny Wong as Stephen Han, current Deputy Commissioner of Police (Operations) / co-conspirator of Peter Choi Ram Chiang as David Mok, Senior Assistant Commissioner of Police, Director of Crime & Security, Phoenix Leung's mentor / co-conspirator of M.B.

Prussian blue or "ferric ferrocyanide", Fe4[Fe(CN)6]3, is an old and well-known iron-cyanide complex, extensively used as pigment and in several other applications. Its formation can be used as a simple wet chemistry test to distinguish between aqueous solutions of Fe2+ and Fe3+ as they react (respectively) with potassium ferricyanide and potassium ferrocyanide to form Prussian blue. Another old example of an organoiron compound is iron pentacarbonyl, Fe(CO)5, in which a neutral iron atom is bound to the carbon atoms of five carbon monoxide molecules. The compound can be used to make carbonyl iron powder, a highly reactive form of metallic iron. Thermolysis of iron pentacarbonyl gives triiron dodecacarbonyl, Fe3(CO)12, a complex with a cluster of three iron atoms at its core. Collman's reagent, disodium tetracarbonylferrate, is a useful reagent for organic chemistry; it contains iron in the −2 oxidation state. Cyclopentadienyliron dicarbonyl dimer contains iron in the rare +1 oxidation state.

Sources: en.wikipedia.org

Supporting material

=== Immune system === BaP has an effect on the number of white blood cells, inhibiting some of them from differentiating into macrophages, the body's first line of defense to fight infections. In 2016, the molecular mechanism was uncovered as damage to the macrophage membrane's lipid raft integrity by decreasing membrane cholesterol at 25%. This means less immunoreceptors CD32 (a member of the Fc family of immunoreceptors) could bind to IgG and turn the white blood cell into a macrophage. Therefore, macrophage membranes become susceptible to bacterial infections.

Functional Genomics Data (FGED) Society Formerly known by the abbreviation MGED. An organization that works with others "to develop standards for biological research data quality, annotation and exchange" as well as software tools that facilitate their use.

The earliest known reference to morphine can be traced back to Theophrastus in the 3rd century BC, however, possible references to morphine may go as far back as 2100 BC as Sumerian clay tablets which records lists of medical prescriptions including opium-based cures. An opium-based elixir has been ascribed to alchemists of Byzantine times, but the specific formula was lost during the Ottoman conquest of Constantinople (Istanbul). Around 1522, Paracelsus made reference to an opium-based elixir that he called laudanum from the Latin word laudāre, meaning "to praise". He described it as a potent painkiller but recommended that it be used sparingly. The recipe given differs substantially from that of modern-day laudanum. Morphine was discovered as the first active alkaloid extracted from the opium poppy plant in December 1804 in Paderborn by German pharmacist Friedrich Sertürner. Sertürner noticed the compound induced drowsiness in rats and stray dogs and he reported his findings in 1805. In 1817, Sertürner reported experiments in which he administered morphine to himself, three young boys, three dogs, and a mouse; all four people almost died. Sertürner originally named the substance morphium after the Greek god of dreams, Morpheus, as it has a tendency to cause sleep. Sertürner's morphium was six times stronger than opium. He hypothesized that, because lower doses of the drug were needed, it would be less addictive.

Necrotizing fasciitis is ideally a clinical diagnosis based on symptoms. Due to the need for rapid surgical treatment, the time delay in performing imaging is a major concern. Hence, imaging may not be needed if signs of a necrotizing infection are clear. However, due to the vague symptoms associated with the earlier stages of this disease, imaging is often useful in clarifying or confirming the diagnosis. Both CT and MRI scans are used to diagnose NF, but neither is sensitive enough to rule out necrotizing changes completely.

Sources: en.wikipedia.org

Frequently asked questions

Tirzepatide 属于哪一类分子?

它属于合成修饰肽,同时激动 GIP 与 GLP-1 两种肠促胰素受体。这类分子通常被称为双重肠促胰素受体激动剂,与选择性 GLP-1 激动剂在靶点范围上不同。

为什么它只需每周给药一次?

分子上的脂肪酸侧链使其与血浆白蛋白结合增强,显著延长循环半衰期。半衰期延长后,稳定血药浓度可在较长的给药间隔内维持,因此常见用法为每周一次。

双靶点设计的意义是什么?

同时激活两条肠促胰素通路可能在胰岛素分泌、胃排空和食欲调节上产生叠加效应。与单靶点相比,临床研究中观察到的血糖与体重变化幅度通常更明显,但各通路的具体贡献比例尚无定论。

What receptor targets does tirzepatide engage?

It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.

Network